{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T14:28:26Z","timestamp":1789828106992,"version":"4.0.1"},"reference-count":54,"publisher":"Bioscientifica","issue":"6","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":289,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Neuroendocrine tumors (NETs) pose a considerable challenge due to their increasing incidence and frequently late-stage diagnosis. The arrival of multikinase inhibitors (MKIs) into clinical practice has brought notable progress in the management of advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This review aims at exploring the impact of MKIs in reshaping the treatment landscape for advanced GEP-NETs. Current approaches in managing advanced GEP-NETs are discussed, including somatostatin analogs, surgery, peptide receptor radionuclide therapy, and approved systemic treatments such as everolimus or sunitinib. The limitations and challenges faced in treating these tumors remain significant. Here, we review the clinical evidence supporting the use of everolimus as a targeted therapy, which has demonstrated improved progression-free survival (PFS), and the need for alternative therapies. Discussions focus on the clinical effectiveness and the emerging role of both established and novel MKIs in the treatment of GEP-NETs, including recent evidence from the CABINET trial and other emerging agents such as surufatinib, axitinib, pazopanib, and lenvatinib. We explore the clinical evidence that showcases sunitinib\u2019s and other MKIs\u2019 effectiveness in prolonging PFS compared to placebo in advanced GEP-NETs. Recently, MKIs have shown to have a significant impact for the treatment of advanced GEP-NETs. There remain several unmet needs that must be addressed, particularly regarding optimal treatment sequencing and the development of predictive biomarkers. Ongoing research and the use of current and emerging MKIs hold great potential to advance the treatment landscape for advanced GEP-NETs significantly.<\/jats:p>","DOI":"10.1530\/erc-25-0052","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T09:44:16Z","timestamp":1747734256000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":9,"title":["Impact of multikinase inhibitors in reshaping the treatment of advanced gastroenteropancreatic neuroendocrine tumors"],"prefix":"10.1530","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5404-2383","authenticated-orcid":true,"given":"Alexander R","family":"Siebenh\u00fcner","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospital Zurich, and University of Zurich 1 , ,","place":["Zurich, Switzerland"]},{"name":"Department Hematology and Oncology, Hirslanden Klinik Zurich 2 , ,","place":["Zurich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Refardt","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes, and Metabolism, Basel University Hospital, Center of Endocrine and Neuroendocrine Tumors, University of Basel 3 , ,","place":["Basel, Switzerland"]},{"name":"Department of Internal Medicine, Section Endocrinology, Erasmus Medical Center Rotterdam 4 , ,","place":["Rotterdam, The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0396-5708","authenticated-orcid":true,"given":"Guillaume P","family":"Nicolas","sequence":"additional","affiliation":[{"name":"Clinic for Radiology and Nuclear Medicine, Center for Neuroendocrine and Endocrine Tumors, University Hospital Basel 5 , ,","place":["Basel, Switzerland"]},{"name":"ENETS Center of Excellence 6 , ,","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8190-8771","authenticated-orcid":true,"given":"Reto","family":"Kaderli","sequence":"additional","affiliation":[{"name":"ENETS Center of Excellence 6 , ,","place":["Basel, Switzerland"]},{"name":"Department of Visceral Surgery and Medicine, Bern University Hospital, University of Bern 7 , ,","place":["Bern, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin A","family":"Walter","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, St. Anna Hospital, University of Lucerne 8 , ,","place":["Lucerne, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurel","family":"Perren","sequence":"additional","affiliation":[{"name":"ENETS Center of Excellence 6 , ,","place":["Basel, Switzerland"]},{"name":"Institute of Tissue Medicine and Pathology, University of Bern 9 , ,","place":["Bern, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5604-4606","authenticated-orcid":true,"given":"Emanuel","family":"Christ","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes, and Metabolism, Basel University Hospital, Center of Endocrine and Neuroendocrine Tumors, University of Basel 3 , ,","place":["Basel, Switzerland"]},{"name":"Clinic for Radiology and Nuclear Medicine, Center for Neuroendocrine and Endocrine Tumors, University Hospital Basel 5 , ,","place":["Basel, Switzerland"]},{"name":"ENETS Center of Excellence 6 , ,","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"key":"2026070905473836900_bib1","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/MPA.0b013e3181ec1261","article-title":"The NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendocrine tumors (nets): well-differentiated nets of the distal colon and rectum","volume":"39","author":"Anthony","year":"2010","journal-title":"Pancreas"},{"key":"2026070905473836900_bib2","first-page":"4140","article-title":"Histopathological basis for targeted therapies in the treatment of gastroenteropancreatic neuroendocrine neoplasms","volume":"12","author":"Barbieri","year":"2023","journal-title":"J Clin Med"},{"key":"2026070905473836900_bib3","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/PAS.0000000000000408","article-title":"The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms","volume":"39","author":"Basturk","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"2026070905473836900_bib4","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1089\/thy.2013.0137","article-title":"In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer","volume":"23","author":"Bentzien","year":"2013","journal-title":"Thyroid"},{"key":"2026070905473836900_bib5","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/MPA.0b013e3181ebb2a5","article-title":"The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum","volume":"39","author":"Boudreaux","year":"2010","journal-title":"Pancreas"},{"key":"2026070905473836900_bib6","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1200\/JCO.20.03368","article-title":"Lenvatinib in patients with advanced grade 1\/2 pancreatic and gastrointestinal neuroendocrine tumors: results of the phase II TALENT trial (GETNE1509)","volume":"39","author":"Capdevila","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026070905473836900_bib8","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11912-017-0633-2","article-title":"Optimizing somatostatin analog use in well or moderately differentiated gastroenteropancreatic neuroendocrine tumors","volume":"19","author":"Carmona-Bayonas","year":"2017","journal-title":"Curr Oncol Rep"},{"key":"2026070905473836900_bib9","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ccr.2005.09.005","article-title":"Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors","volume":"8","author":"Casanovas","year":"2005","journal-title":"Cancer Cell"},{"key":"2026070905473836900_bib10","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa2403991","article-title":"Phase 3 trial of cabozantinib to treat advanced neuroendocrine tumors","volume":"392","author":"Chan","year":"2025","journal-title":"N Engl J Med"},{"key":"2026070905473836900_bib11","first-page":"951","article-title":"The tumor microenvironment in neuroendocrine tumors: biology and therapeutic implications","volume":"110","author":"Cives","year":"2020","journal-title":"Neuroendocrinology"},{"key":"2026070905473836900_bib12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11912-021-01029-7","article-title":"Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences?","volume":"23","author":"Das","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"2026070905473836900_bib13","article-title":"Efficacy and safety of lenvatinib in patients with neuroendocrine neoplasms","volume":"13","author":"Di Mauro","year":"2022","journal-title":"Front Endocrinol"},{"key":"2026070905473836900_bib14","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/annonc\/mdw561","article-title":"Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study","volume":"28","author":"Faivre","year":"2017","journal-title":"Ann Oncol"},{"key":"2026070905473836900_bib15","doi-asserted-by":"crossref","first-page":"7557","DOI":"10.3390\/jcm12247557","article-title":"Predictive factors of response to streptozotocin in neuroendocrine pancreatic neoplasms","volume":"12","author":"Fanciulli","year":"2023","journal-title":"J Clin Med"},{"key":"2026070905473836900_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2023.101794","article-title":"Precision medicine in gastroenteropancreatic neuroendocrine neoplasms: where are we in 2023?","volume":"37","author":"Fazio","year":"2023","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2026070905473836900_bib17","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(17)30110-9","article-title":"Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study","volume":"18","author":"Halperin","year":"2017","journal-title":"Lancet Oncol"},{"key":"2026070905473836900_bib18","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1200\/JCO.2014.56.2082","article-title":"Multicenter phase II trial of temsirolimus and bevacizumab in pancreatic neuroendocrine tumors","volume":"33","author":"Hobday","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026070905473836900_bib20","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1677\/ERC-10-0126","article-title":"mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours","volume":"18","author":"Kasajima","year":"2011","journal-title":"Endocr Relat Cancer"},{"key":"2026070905473836900_bib54","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1200\/JCO.2007.15.9020","article-title":"Activity of sunitinib in patients with advanced neuroendocrine tumors","volume":"26","author":"Kulke","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026070905473836900_bib21","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/bjc.2017.402","article-title":"Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response","volume":"118","author":"Lamarca","year":"2018","journal-title":"Br J Cancer"},{"key":"2026070905473836900_bib22","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1080\/14656566.2018.1476492","article-title":"Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence","volume":"19","author":"Lee","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"2026070905473836900_bib24","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.hpb.2019.08.011","article-title":"ALPPS in neuroendocrine liver metastases not amenable for conventional resection \u2013 lessons learned from an interim analysis of the International ALPPS Registry","volume":"22","author":"Linecker","year":"2019","journal-title":"HPB"},{"key":"2026070905473836900_bib25","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/MPA.0000000000000262","article-title":"Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial","volume":"44","author":"Lombard-Bohas","year":"2015","journal-title":"Pancreas"},{"key":"2026070905473836900_bib26","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/BF03262203","article-title":"Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook","volume":"16","author":"Mateo","year":"2012","journal-title":"Mol Diagn Ther"},{"key":"2026070905473836900_bib27","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study","volume":"378","author":"Pavel","year":"2011","journal-title":"Lancet"},{"key":"2026070905473836900_bib28","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000443167","article-title":"ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site","volume":"103","author":"Pavel","year":"2016","journal-title":"Neuroendocrinology"},{"key":"2026070905473836900_bib29","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/annonc\/mdx193","article-title":"Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study","volume":"28","author":"Pavel","year":"2017","journal-title":"Ann Oncol"},{"key":"2026070905473836900_bib30","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/cpt.559","article-title":"Effect of everolimus on the pharmacokinetics of octreotide long-acting repeatable in patients with advanced neuroendocrine tumors: an analysis of the randomized phase III RADIANT-2 trial","volume":"101","author":"Pavel","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"2026070905473836900_bib31","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1159\/000471880","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: systemic therapy \u2013 biotherapy and novel targeted agents","volume":"105","author":"Pavel","year":"2017","journal-title":"Neuroendocrinology"},{"key":"2026070905473836900_bib32","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy293.028","article-title":"Compete trial: peptide receptor radionuclide therapy (PRRT) with 177Lu-edotreotide vs. everolimus in progressive GEP-NET","volume":"29","author":"Pavel","year":"2018","journal-title":"Ann Oncol"},{"key":"2026070905473836900_bib33","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/annonc\/mdz222","article-title":"Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study","volume":"30","author":"Pavel","year":"2019","journal-title":"Ann Oncol"},{"key":"2026070905473836900_bib34","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann Oncol"},{"key":"2026070905473836900_bib35","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/MPA.0b013e3181ec1380","article-title":"NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus)","volume":"39","author":"Phan","year":"2010","journal-title":"Pancreas"},{"key":"2026070905473836900_bib36","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S1470-2045(15)70136-1","article-title":"Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study","volume":"16","author":"Phan","year":"2015","journal-title":"Lancet Oncol"},{"key":"2026070905473836900_bib37","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"key":"2026070905473836900_bib56","doi-asserted-by":"crossref","first-page":"S1412","DOI":"10.1016\/j.annonc.2022.08.044","article-title":"LBA45 Randomized open label phase III study comparing the efficacy and safety of everolimus followed by chemotherapy (CT) with streptozotocin (STZ)-5FU upon progression or the reverse sequence, in advanced progressive panNETs: the SEQTOR study (GETNE 1206)","volume":"33","author":"Salazar","year":"2022","journal-title":"Ann Oncol"},{"key":"2026070905473836900_bib38","doi-asserted-by":"crossref","first-page":"693","DOI":"10.6004\/jnccn.2018.0056","article-title":"NCCN guidelines insights: neuroendocrine and adrenal tumors, version 2.2018","volume":"16","author":"Shah","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"2026070905473836900_bib39","doi-asserted-by":"crossref","first-page":"42","DOI":"10.21037\/gs.2017.12.11","article-title":"Liver transplantation for unresectable pancreatic neuroendocrine tumors with liver metastases in an era of transplant oncology","volume":"7","author":"Shimata","year":"2018","journal-title":"Gland Surg"},{"key":"2026070905473836900_bib40","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"2026070905473836900_bib55","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","article-title":"[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high\u2011dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet"},{"key":"2026070905473836900_bib41","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/107327481101800207","article-title":"A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract","volume":"18","author":"Strosberg","year":"2011","journal-title":"Cancer Control"},{"key":"2026070905473836900_bib42","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1530\/ERC-16-0008","article-title":"A phase II study of axitinib in advanced neuroendocrine tumors","volume":"23","author":"Strosberg","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"2026070905473836900_bib43","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/MPA.0000000000000850","article-title":"The North American neuroendocrine tumor society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors","volume":"46","author":"Strosberg","year":"2017","journal-title":"Pancreas"},{"key":"2026070905473836900_bib44","first-page":"1328","article-title":"177Lu-DOTATATE plus long-acting octreotide versus high-dose long-acting octreotide in treatment-na\u00efve well-differentiated gastroenteropancreatic neuroendocrine tumours with high proliferation activity (NETTER-2): a randomised, open-label, phase 3 trial","volume":"403","author":"Strosberg","year":"2024","journal-title":"Lancet"},{"key":"2026070905473836900_bib45","first-page":"202","article-title":"Surufatinib reduces tumor-induced immunosuppression and synergizes with anti-programmed cell death-1 to inhibit tumor growth in non-small cell lung cancer","volume":"23","author":"Wu","year":"2021","journal-title":"J Clin Transl Oncol"},{"key":"2026070905473836900_bib46","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S1470-2045(20)30493-9","article-title":"Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Xu","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026070905473836900_bib47","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/S1470-2045(20)30496-4","article-title":"Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Xu","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026070905473836900_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115398","article-title":"Surufatinib in advanced neuroendocrine tumours: final overall survival from two randomised, double-blind, placebo-controlled phase 3 studies (SANET-ep and SANET-p)","volume":"222","author":"Xu","year":"2025","journal-title":"Eur J Cancer"},{"key":"2026070905473836900_bib48","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026070905473836900_bib49","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1200\/JCO.2008.16.7858","article-title":"Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026070905473836900_bib50","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"2026070905473836900_bib51","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"key":"2026070905473836900_bib52","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1200\/JCO.2016.68.0702","article-title":"Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: overall survival and circulating biomarkers from the randomized, phase III RADIANT-3 study","volume":"34","author":"Yao","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026070905473836900_bib53","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/jnci\/djt135","article-title":"Current understanding of the molecular biology of pancreatic neuroendocrine tumors","volume":"105","author":"Zhang","year":"2013","journal-title":"J Natl Cancer Inst"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/32\/6\/ERC-25-0052.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/32\/6\/ERC-25-0052.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-25-0052\/247020\/erc-25-0052.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-25-0052\/247020\/erc-25-0052.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T09:47:47Z","timestamp":1783590467000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/32\/6\/e250052\/26026\/Impact-of-multikinase-inhibitors-in-reshaping-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1530\/erc-25-0052","relation":{},"ISSN":["1479-6821","1351-0088"],"issn-type":[{"value":"1479-6821","type":"electronic"},{"value":"1351-0088","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,20]]},"article-number":"e250052"}}